Literature DB >> 26740316

Ankle-Brachial Index and cardiovascular events in atrial fibrillation. The ARAPACIS Study.

Francesco Violi1, Giovanni Davì, Marco Proietti, Daniele Pastori, William R Hiatt, Gino Roberto Corazza, Francesco Perticone, Pasquale Pignatelli, Alessio Farcomeni, Anna Rita Vestri, Gregory Y H Lip, Stefania Basili.   

Abstract

Atrial fibrillation (AF) patients are at high risk for thrombotic and vascular events related to their cardiac arrhythmia and underlying systemic atherosclerosis. Ankle-Brachial Index (ABI) is a non-invasive tool in evaluating systemic atherosclerosis, useful in predicting cardiovascular events in general population; no data are available in AF patients. ARAPACIS is a prospective multicentre observational study performed by the Italian Society of Internal Medicine, analysing association between low ABI (≤ 0.90) and vascular events in NVAF out- or in-patients, enrolled in 136 Italian centres. A total of 2,027 non-valvular AF (NVAF) patients aged > 18 years from both sexes followed for a median time of 34.7 (interquartile range: 22.0-36.0) months, yielding a total of 4,614 patient-years of observation. Mean age was 73 ± 10 years old with 55 % male patients. A total of 176 patients (8.7 %) experienced a vascular event, with a cumulative incidence of 3.81 %/patient-year. ABI≤ 0.90 was more prevalent in patients with a vascular event compared with patients free of vascular events (32.2 vs 20.2 %, p< 0.05). On Cox proportional hazard analysis, ABI≤ 0.90 was an independent predictor of vascular events (hazard ratio (HR): 1.394, 95 % confidence interval (CI): 1.042-1.866; p=0.02), vascular death (HR: 2.047, 95 % CI: 1.255-3.338; p=0.004) and MI (HR: 2.709, 95 % CI: 1.485-5.083; p=0.001). This latter association was also confirmed after excluding patients with previous MI (HR: 2.901, 95 % CI: 1.408-5.990, p=0.004). No association was observed between low ABI and stroke/transient ischaemic attack (p=0.91). In conclusion, low ABI is useful to predict MI and vascular death in NVAF patients and may independently facilitate cardiovascular risk assessment in NVAF patients.

Entities:  

Keywords:  ABI; ARAPACIS; Atrial fibrillation; myocardial infarction; vascular events

Mesh:

Year:  2016        PMID: 26740316     DOI: 10.1160/TH15-07-0612

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

1.  Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study.

Authors:  Valeria Raparelli; Daniele Pastori; Serena Francesca Pignataro; Anna Rita Vestri; Pasquale Pignatelli; Roberto Cangemi; Marco Proietti; Giovanni Davì; William Robert Hiatt; Gregory Yoke Hong Lip; Gino Roberto Corazza; Francesco Perticone; Francesco Violi; Stefania Basili
Journal:  Intern Emerg Med       Date:  2018-03-26       Impact factor: 3.397

2.  Aging-Related Decline of Glutathione Peroxidase 3 and Risk of Cardiovascular Events in Patients With Atrial Fibrillation.

Authors:  Daniele Pastori; Pasquale Pignatelli; Alessio Farcomeni; Danilo Menichelli; Cristina Nocella; Roberto Carnevale; Francesco Violi
Journal:  J Am Heart Assoc       Date:  2016-09-08       Impact factor: 5.501

3.  Predictive value of CHADS2 and CHA2DS2-VASc scores for acute myocardial infarction in patients with atrial fibrillation.

Authors:  Hui Pang; Bing Han; Qiang Fu; Zhenkun Zong
Journal:  Sci Rep       Date:  2017-07-05       Impact factor: 4.379

4.  Association of Peripheral Artery Disease With Incident Atrial Fibrillation: The ARIC (Atherosclerosis Risk in Communities) Study.

Authors:  Wobo Bekwelem; Faye L Norby; Sunil K Agarwal; Kunihiro Matsushita; Josef Coresh; Alvaro Alonso; Lin Y Chen
Journal:  J Am Heart Assoc       Date:  2018-04-17       Impact factor: 5.501

5.  Usefulness of the ratio of brachial pre-ejection period to brachial ejection time in prediction of cardiovascular and overall mortality in patients with acute myocardial infarction.

Authors:  Ho-Ming Su; Wen-Hsien Lee; Wei-Chung Tsai; Ying-Chih Chen; Nai-Yu Chi; Ching-Tang Chang; Chun-Yuan Chu; Tsung-Hsien Lin; Wen-Ter Lai; Sheng-Hsiung Sheu; Po-Chao Hsu
Journal:  PLoS One       Date:  2021-01-29       Impact factor: 3.240

6.  The Impact of Atrial Fibrillation on One-Year Mortality in Patients with Severe Lower Extremity Arterial Disease.

Authors:  Min-I Su; Ying-Chih Cheng; Yu-Chen Huang; Cheng-Wei Liu
Journal:  J Clin Med       Date:  2022-03-31       Impact factor: 4.241

7.  Clinical complexity and impact of the ABC (Atrial fibrillation Better Care) pathway in patients with atrial fibrillation: a report from the ESC-EHRA EURObservational Research Programme in AF General Long-Term Registry.

Authors:  Giulio Francesco Romiti; Marco Proietti; Giuseppe Boriani; Gregory Y H Lip; Marco Vitolo; Niccolò Bonini; Ameenathul Mazaya Fawzy; Wern Yew Ding; Laurent Fauchier; Francisco Marin; Michael Nabauer; Gheorghe Andrei Dan; Tatjana S Potpara
Journal:  BMC Med       Date:  2022-09-02       Impact factor: 11.150

Review 8.  Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms.

Authors:  Francesco Violi; Elsayed Z Soliman; Pasquale Pignatelli; Daniele Pastori
Journal:  J Am Heart Assoc       Date:  2016-05-20       Impact factor: 5.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.